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Background: Although the negative prognostic impact of reduced pre-PCI TIMI flow is well known in STEMI, whether this is true among pts with 
acute coronary syndromes (ACS) has never been examined.
Methods: We evaluated 3,619 ACS pts undergoing PCI enrolled in the ACUITY trial formal angiographic substudy. Pts were divided in 3 groups 
according to pre-procedural TIMI flow (TIMI 0-1, TIMI 2 and TIMI 3 flow), determined by an independent angiographic core lab.
Results: Baseline culprit vessel flow was absent (TIMI 0/1) in 547 (15.1%) pts, reduced (TIMI 2) in 392 (10.8%) and normal (TIMI 3) in 2,680 
(74.1%). Post PCI, TIMI 3 flow was achieved in 86.2%, 88.5% and 98.4% of the 3 groups respectively (p < 0.0001). At 1 year, the composite of 
death, MI or unplanned revascularization occurred in 19.9%, 17.5% and 21.6% of pts with baseline TIMI 0/1, 2 and 3 flow, respectively (P=0.19). 
By multivariable analysis lower EF, insulin-treated diabetes, prior PCI, chronic kidney disease and bare metal stent (vs. drug-eluting stent) were 
independent correlates of increased 1-year composite ischemic events. Pre-PCI TIMI flow 0/1 (vs. TIMI 3 flow) did not significantly affect the 
composite outcome (P=0.82), or its individual components (Table).
Conclusions: In contrast to STEMI, pre-PCI TIMI flow in moderate and high risk pts with ACS undergoing PCI does not independently predict future 
adverse ischemic events. These findings are important in crafting policies and trials for timing and aggressiveness of revascularization in ACS.
1-year ciinical outcome
Preprocedural TIMI flow 0-1 2 3 Unadjusted P value TIMI 0-1 vs 3
Adjusted P value TIMI 0-1 
vs 3
(n = 547) (n = 392) (n = 2680)
Death, MI or unplanned revascularization 19.9% 17.5% 21.6% 0.32 0.82
Death 2.6% 1.8% 3.1% 0.61 0.68
MI 9.4% 9.5% 10.9% 0.36 0.36
Unplanned Revascularization 13.2% 10.4% 13.9% 0.60 0.34
